Qui Tran

3.3k total citations · 2 hit papers
35 papers, 679 citations indexed

About

Qui Tran is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Qui Tran has authored 35 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Hematology. Recurrent topics in Qui Tran's work include Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (10 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Qui Tran is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (10 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Qui Tran collaborates with scholars based in United States, Japan and France. Qui Tran's co-authors include Max S. Topp, Marwan Fakih, Emily Chan, Anthony S. Stein, Andre C. Schuh, Joseph Chao, David Cunningham, Julien Taı̈eb, Kun‐Huei Yeh and Chiara Cremolini and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Qui Tran

34 papers receiving 673 citations

Hit Papers

Sotorasib plus Panitumumab in Refractory Colorectal Cance... 2023 2026 2024 2025 2023 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    2023 163 citations Marwan Fakih, Lisa Salvatore et al. profile →
  2. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
    2024 49 citations Yasutoshi Kuboki, Marwan Fakih et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qui Tran United States 13 439 208 155 132 124 35 679
Elaine Murray United States 9 198 0.5× 182 0.9× 187 1.2× 79 0.6× 195 1.6× 11 716
Lu Yu China 16 383 0.9× 158 0.8× 38 0.2× 109 0.8× 36 0.3× 48 685
Cristina Martín Spain 12 550 1.3× 557 2.7× 142 0.9× 245 1.9× 53 0.4× 22 1.1k
Shilpa Paul United States 13 232 0.5× 122 0.6× 52 0.3× 86 0.7× 199 1.6× 41 670
Nicolas Rouyrre United States 14 263 0.6× 251 1.2× 106 0.7× 122 0.9× 30 0.2× 27 641
Sandra Quijano Colombia 13 149 0.3× 148 0.7× 236 1.5× 92 0.7× 118 1.0× 40 661
Mark Cornfeld United States 11 497 1.1× 294 1.4× 122 0.8× 151 1.1× 16 0.1× 33 838
Dominique Cazals France 9 247 0.6× 138 0.7× 143 0.9× 68 0.5× 56 0.5× 11 525
Laure Farnault France 11 185 0.4× 119 0.6× 51 0.3× 68 0.5× 28 0.2× 38 549
Claudia Corrado Argentina 14 265 0.6× 207 1.0× 336 2.2× 109 0.8× 57 0.5× 28 661

Countries citing papers authored by Qui Tran

Since Specialization
Citations

This map shows the geographic impact of Qui Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qui Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qui Tran more than expected).

Fields of papers citing papers by Qui Tran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qui Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qui Tran. The network helps show where Qui Tran may publish in the future.

Co-authorship network of co-authors of Qui Tran

This figure shows the co-authorship network connecting the top 25 collaborators of Qui Tran. A scholar is included among the top collaborators of Qui Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qui Tran. Qui Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pietrantonio, Filippo, Lisa Salvatore, Taito Esaki, et al.. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. 43(19). 2147–2154. 7 indexed citations
2.
3.
Kuboki, Yasutoshi, Marwan Fakih, John H. Strickler, et al.. (2024). Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature Medicine. 30(1). 265–270. 49 indexed citations breakdown →
4.
Fakih, Marwan, Lisa Salvatore, Taito Esaki, et al.. (2024). Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 42(17_suppl). LBA3510–LBA3510. 7 indexed citations
5.
Modest, Dominik Paul, Marwan Fakih, Lisa Salvatore, et al.. (2024). Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.. Journal of Clinical Oncology. 42(3_suppl). 10–10. 2 indexed citations
6.
Pietrantonio, Filippo, Lisa Salvatore, Taito Esaki, et al.. (2023). LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study. Annals of Oncology. 34. S1266–S1266. 3 indexed citations
7.
Hong, David S., Yasutoshi Kuboki, John H. Strickler, et al.. (2023). Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.. Journal of Clinical Oncology. 41(16_suppl). 3513–3513. 16 indexed citations
8.
9.
10.
Hong, David S., Rona Yaeger, Yasutoshi Kuboki, et al.. (2022). A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).. Journal of Clinical Oncology. 40(4_suppl). TPS214–TPS214. 11 indexed citations
11.
Strickler, John H., Hironaga Satake, Antoine Hollebecque, et al.. (2022). First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. Journal of Clinical Oncology. 40(36_suppl). 360490–360490. 32 indexed citations
12.
Skoulidis, Ferdinandos, Gerald S. Falchook, Adrian G. Sacher, et al.. (2021). PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. Journal of Thoracic Oncology. 16(3). S61–S61. 25 indexed citations
13.
Toto, Robert D., et al.. (2020). A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology. 32(2). 469–478. 1 indexed citations
14.
Wang, Zheng, Alicia Zhang, Yuqi Chen, Qui Tran, & Chris Holland. (2020). Type I error inflation of log-rank test with small sample size : A permutation approach and simulation studies. 53(2). 93–109. 1 indexed citations
15.
Jabbour, Elias, Nicola Gökbuget, Hagop M. Kantarjian, et al.. (2019). Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 125(23). 4181–4192. 53 indexed citations
16.
Topp, Max S., Paul Cannell, Hervé Dombret, et al.. (2018). Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 131(26). 2906–2914. 36 indexed citations
17.
Tran, Qui, Kelley M. Kidwell, & Alex Tsodikov. (2017). A joint model of cancer incidence, metastasis, and mortality. Lifetime Data Analysis. 24(3). 385–406. 1 indexed citations
18.
Tran, Qui, Beverley Adams‐Huet, Mary‐Margaret Chren, et al.. (2012). A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology. 168(1). 145–153. 47 indexed citations
19.
Moraleda, José M., et al.. (2004). Gene expression data analytics with interlaboratory validation for identifying anatomical sites of origin of metastatic carcinomas. Journal of Clinical Oncology. 22(14_suppl). 9625–9625. 6 indexed citations
20.
Tran, Qui, Hitoshi Takamura, & Makoto Kito. (1992). Dried Soy Milk with Low Content ofn-Hexanal. Bioscience Biotechnology and Biochemistry. 56(3). 519–520. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elaine Murray Breakdown of academic impact, for papers by Lu Yu Breakdown of academic impact, for papers by Cristina Martín Breakdown of academic impact, for papers by Shilpa Paul Breakdown of academic impact, for papers by Nicolas Rouyrre Breakdown of academic impact, for papers by Sandra Quijano Breakdown of academic impact, for papers by Mark Cornfeld Breakdown of academic impact, for papers by Dominique Cazals Breakdown of academic impact, for papers by Laure Farnault Breakdown of academic impact, for papers by Claudia Corrado
Rankless by CCL
2026